For the year ending 2025-12-31, TNDM had $21,400K increase in cash & cash equivalents over the period. -$29,669K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -204,710 |
| Depreciation and amortization expense | 17,666 |
| Amortization of debt issuance costs | 1,860 |
| Provision for expected credit losses | 9,478 |
| Operating lease and other impairment charges | 6,697 |
| Amortization of discount or (accretion of premium) on short-term investments | 3,828 |
| Loss from equity method investments | -14,194 |
| Stock-based compensation expense | 92,381 |
| Loss on extinguishment of debt | 0 |
| Acquired in-process research and development expenses | 75,217 |
| Other | 4,363 |
| Accounts receivable, net | 56,812 |
| Inventories | -24,816 |
| Prepaid and other current assets | 9,088 |
| Other long-term assets | 6,888 |
| Accounts payable | 2,227 |
| Accrued expenses | -664 |
| Employee-related liabilities | 5,995 |
| Deferred revenue | -4,788 |
| Operating leases and other current liabilities | 19,225 |
| Other long-term liabilities | 2,938 |
| Net cash provided by (used in) operating activities | -9,721 |
| Purchases of short-term investments | 85,660 |
| Proceeds from maturities and redemptions of short-term investments | 257,072 |
| Purchases of property and equipment | 19,948 |
| Acquisition of in-process research and development | 78,588 |
| Purchases of equity investments, strategic investments, and intangible assets | 0 |
| Net cash provided by (used in) investing activities | 72,876 |
| Proceeds from issuance of convertible senior notes due 2029, net of 9,400 debt issuance costs | 0 |
| Repurchase of 246,740 principal amount of convertible senior notes due 2025 | 0 |
| Principal payments on convertible senior notes due 2025 | 40,760 |
| Payment for capped call transactions related to convertible senior notes due 2029 | 0 |
| Repurchase and retirement of common stock | 0 |
| Cash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under company stock plans | 2,607 |
| Other financing activities | 0 |
| Net cash provided by (used in) financing activities | -43,367 |
| Effect of foreign exchange rate changes on cash | 1,612 |
| Net increase (decrease) in cash and cash equivalents | 21,400 |
| Cash and cash equivalents at beginning of period | 69,234 |
| Cash and cash equivalents at end of period | 90,634 |
TANDEM DIABETES CARE INC (TNDM)
TANDEM DIABETES CARE INC (TNDM)